Form 4: Pasithea Therapeutics Director Acquires Stock Options

Lawrence Steinman, a director of Pasithea Therapeutics Corp., was granted stock options to purchase 7,500 shares of common stock on March 1, 2024.

Summary

• On March 1, 2024, Lawrence Steinman, a director of Pasithea Therapeutics Corp., acquired stock options for 7,500 shares.
• The options were granted under the company's 2023 Stock Incentive Plan.
• The exercise price of the options is $8.34.
• The options vest in three annual installments of 33% starting on the one-year anniversary of the grant date, contingent upon continued service as a director.
• The options expire on February 28, 2034.
• A reverse stock split of 1-for-20 was effected on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of aligning director interests with shareholders, but it's not a major event.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The director's continued service is tied to the vesting of the stock options, suggesting an ongoing commitment to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, director, Pasithea Therapeutics, KTTA, reverse stock split, equity awards, beneficial ownership, Form 4